arrow_back Back Filing freshness 10-Q Q4 FY2028 SEC EDGAR

TuHURA Biosciences, Inc./NV

HURA
$2.12 ▲ +0.01 (+0.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
21 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, TuHURA Biosciences, Inc./NV shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-7.54M
↓ -13.1%
FCF / Share Free cash flow per share
$-0.07
↑ +32.5%
Long-Term Debt Long-term obligations
$1.12K
↓ -96.0%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of -0.79x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 52 quarters